sibutramine has been researched along with Depression in 15 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To reveal whether baseline body mass index (BMI), and psychobehavioral and nutritional markers were significant predictors of the change in BMI observed after 4 and 12 months in obese women enrolled in a weight reduction program, including low-energy diet, increased physical activity, cognitive behavior therapy and sibutramine." | 9.11 | Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine. ( Bellisle, F; Braunerova, R; Hainer, V; Hill, M; Kunesova, M; Wagenknecht, M, 2005) |
| "The aim of the study was to study the role of initial eating behaviour for subsequent weight loss in treatment with sibutramine (Reductil, Meridia) an anti-obesity drug enhancing satiety, and also to assess changes in mood during the treatment." | 9.11 | Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood. ( Barkeling, B; Elfhag, K; Rooth, P; Rössner, S, 2005) |
| "Obesity was induced by high-fat diet (HFD) in healthy male Sprague-Dawley rats." | 5.35 | Evaluation of anti-obesity activity of duloxetine in comparison with sibutramine along with its anti-depressant activity: an experimental study in obese rats. ( Bhatt, PA; Chudasama, HP, 2009) |
| "To reveal whether baseline body mass index (BMI), and psychobehavioral and nutritional markers were significant predictors of the change in BMI observed after 4 and 12 months in obese women enrolled in a weight reduction program, including low-energy diet, increased physical activity, cognitive behavior therapy and sibutramine." | 5.11 | Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine. ( Bellisle, F; Braunerova, R; Hainer, V; Hill, M; Kunesova, M; Wagenknecht, M, 2005) |
| "The aim of the study was to study the role of initial eating behaviour for subsequent weight loss in treatment with sibutramine (Reductil, Meridia) an anti-obesity drug enhancing satiety, and also to assess changes in mood during the treatment." | 5.11 | Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood. ( Barkeling, B; Elfhag, K; Rooth, P; Rössner, S, 2005) |
| "Overweight and obesity are major factors contributing to the development of type 2 diabetes mellitus (DM) and cardiovascular disease (CVD)." | 1.35 | The endocannabinoid system as a target for obesity treatment. ( Aronne, LJ; Davis, SN; Foster, GD; Pagotto, U, 2008) |
| "Obesity was induced by high-fat diet (HFD) in healthy male Sprague-Dawley rats." | 1.35 | Evaluation of anti-obesity activity of duloxetine in comparison with sibutramine along with its anti-depressant activity: an experimental study in obese rats. ( Bhatt, PA; Chudasama, HP, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (93.33) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balavoine, F | 1 |
| Malabre, P | 1 |
| Alleaume, T | 1 |
| Rey, A | 1 |
| Cherfils, V | 1 |
| Jeanneton, O | 1 |
| Seigneurin-Venin, S | 1 |
| Revah, F | 1 |
| Zhuang, J | 1 |
| Wang, X | 1 |
| Xu, L | 1 |
| Wu, T | 1 |
| Kang, D | 1 |
| Slovacek, L | 1 |
| Pavlik, V | 1 |
| Slovackova, B | 1 |
| Aronne, LJ | 1 |
| Pagotto, U | 1 |
| Foster, GD | 1 |
| Davis, SN | 1 |
| Faulconbridge, LF | 1 |
| Wadden, TA | 2 |
| Berkowitz, RI | 1 |
| Sarwer, DB | 1 |
| Womble, LG | 1 |
| Hesson, LA | 1 |
| Stunkard, AJ | 1 |
| Fabricatore, AN | 2 |
| Rihmer, Z | 1 |
| Purebl, G | 1 |
| Faludi, G | 1 |
| Halmy, L | 1 |
| Huang, BC | 1 |
| Liou, HH | 1 |
| Moore, RH | 1 |
| Butryn, ML | 1 |
| Heymsfield, SB | 1 |
| Nguyen, AM | 1 |
| Chudasama, HP | 1 |
| Bhatt, PA | 1 |
| Hainer, V | 2 |
| Kunesova, M | 2 |
| Bellisle, F | 1 |
| Hill, M | 1 |
| Braunerova, R | 1 |
| Wagenknecht, M | 2 |
| Elfhag, K | 1 |
| Rössner, S | 1 |
| Barkeling, B | 1 |
| Rooth, P | 1 |
| Kabrnova, K | 1 |
| Aldhoon, B | 1 |
| Yilmaz, Y | 1 |
| Nau, JY | 1 |
| Aylwin, S | 1 |
| Al-Zaman, Y | 1 |
4 reviews available for sibutramine and Depression
| Article | Year |
|---|---|
Antidepressants for polycystic ovary syndrome.
Topics: Antidepressive Agents; Cyclobutanes; Depression; Female; Fluoxetine; Humans; Polycystic Ovary Syndro | 2013 |
[Association of obesity and depression].
Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Appetite Regulation; Bipolar Disor | 2008 |
Serotonin and norepinephrine reuptake inhibition and eating behavior.
Topics: Abdominal Fat; Antidepressive Agents; Appetite Depressants; Body Weight; Cyclobutanes; Depression; E | 2006 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria | 2008 |
4 trials available for sibutramine and Depression
| Article | Year |
|---|---|
Changes in symptoms of depression with weight loss: results of a randomized trial.
Topics: Adult; Affect; Appetite Depressants; Behavior Control; Behavior Therapy; Cyclobutanes; Depression; F | 2009 |
Predictors of attrition and weight loss success: Results from a randomized controlled trial.
Topics: Adult; Age Factors; Appetite Depressants; Body Weight; Combined Modality Therapy; Cyclobutanes; Depr | 2009 |
Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Body Mass Index; Cognitive Behavioral Therapy; Combin | 2005 |
Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood.
Topics: Adult; Affect; Cyclobutanes; Depression; Feeding Behavior; Female; Humans; Male; Middle Aged; Obesit | 2005 |
7 other studies available for sibutramine and Depression
| Article | Year |
|---|---|
Design and synthesis of novel hydantoin-containing melanin-concentrating hormone receptor antagonists.
Topics: Animals; Chemistry, Pharmaceutical; Depression; Disease Models, Animal; Drug Design; Feeding Behavio | 2007 |
The effect of sibutramine therapy on occurrence of depression symptoms among obese patients.
Topics: Antidepressive Agents; Appetite Depressants; Body Mass Index; Cyclobutanes; Depression; Humans; Long | 2008 |
The endocannabinoid system as a target for obesity treatment.
Topics: Amides; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Cyclobutanes; Depression; Endocannabin | 2008 |
Sibutramine-induced recurrent seizures.
Topics: Adult; Antidepressive Agents; Cyclobutanes; Depression; Female; Humans; Seizures | 2009 |
Evaluation of anti-obesity activity of duloxetine in comparison with sibutramine along with its anti-depressant activity: an experimental study in obese rats.
Topics: Adiposity; Animals; Anti-Obesity Agents; Antidepressive Agents; Appetite Regulation; Blood Pressure; | 2009 |
Psychopathology in the context of obesity: the adiponectin hypothesis.
Topics: Adiponectin; Anxiety; Cyclobutanes; Depression; Headache; Humans; Migraine Disorders; Models, Biolog | 2008 |
[Antiobesity drugs--new limitations].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Depression; Drug Therapy, Combination; Evid | 2007 |